The Release Trial: a randomised controlled trial of umbilical vein oxytocin versus placebo for the treatment of retained placenta.

Abstract

Intraumbilical injection of oxytocin reduces the incidence of manual removal compared with placebo in the treatment of retained placenta. ENTRY CRITERIA: The women recruited will be stable haemodynamically, not bleeding vaginally, over 34 weeks of gestation and with a retained placenta for at least 30 minutes. TREATMENT ARMS: Oxytocin (50 IU) or sterile water (in identical vials) in 25 mL saline injected through an intraumbilical venous catheter. Five hundred seventy-two women. Need for manual removal of placenta. CENTRES: Initially, there will be two study sites in the UK (Liverpool and Sheffield) and five in Uganda (Mulago, Nsambia, Mengo, Rubaga and Arua). World Health Organization and WellBeing of Women.